Finalists Selected for the 23rd Annual Gardere MLK Jr. Oratory Competition
10 December 2014
Dallas Independent School District’s publication, thehub, featured the 23rd Annual Gardere MLK Jr. Oratory Semifinal Competition held on Dec. 9. Students representing 15 Dallas ISD schools presented original speeches answering the question, “If Dr. King were to win the Nobel Peace Prize today, what would he say in his acceptance speech?”
The students advancing to the final competition scheduled for Jan. 16, 2015 at the Majestic Theatre are:
- Kywin Brown, fourth grade, Wilmer-Hutchins Elementary
- Serenity Dugan, fourth grade, Thomas L. Marsalis Elementary
- Jalien Hedgeman, fifth grade, Clara Oliver Elementary
- Walker Homan, fifth grade, Harry C. Withers Elementary
- Etana King, fifth grade, John Neely Bryan Elementary
- Camilla Meza, fifth grade, Thomas Tolbert Elementary
- Hannah Wesley, fifth grade, Charles Rice Learning Center
- Aisha Young, fifth grade, William Brown Miller Elementary
The complete article can be viewed here. For more information about the Gardere MLK Jr. Oratory competition, including video of past winning speeches, click here.
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”